Knome Launches the knoSYS™ 25 Human Genome Interpretation Platform
CAMBRIDGE, MA – March 26, 2014 – Knome, Inc. announced the launch of a new addition to the knoSYS human genome interpretation platform product line. Debuting today at the annual meeting of the American College of Medical Genetics and Genomics in Nashville, Tennessee, the knoSYS™ 25 model addresses the needs of laboratories that focus on targeted panels and lesser numbers of whole exomes and genomes.
The knoSYS platform is an end-to-end solution for the operational needs of clinical labs that are developing tests based on next generation sequencing (NGS). Users can process raw data through all the remaining steps of analysis: sequence alignment, variant calling, quality control, annotation, filtering, and reporting. The premier knoSYS™ 100 model, launched in 2012, is built to power high volume testing of exomes and genomes. Introduction of the slimmed down and lower-priced knoSYS™ 25 model is Knome’s response to demand from customers with smaller computational requirements.
“We see a growing need for our products in commercial and academic clinical labs adopting NGS,” said Knome CEO Wolfgang Daum. “By providing the entry-level knoSYS™ 25 model, Knome is helping smaller labs make their initial foray into NGS genomics.”
“The knoSYS platform provides a secure, fast computing environment behind the customer’s firewall and encapsulates the lab’s expertise and access to the public and institutional knowledge needed to provide the timely, reproducible, high quality services their own customers require.”
For more information visit www.knome.com, or contact Jorge Conde, [email protected], 617-715-1000 x2001.
About Knome
Knome Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to pave the healthcare industry’s transition to molecular-based, precision medicine. www.knome.com.
###